Syntara Ltd (ASX:SNT)
A$ 0.056 0.006 (12%) Market Cap: 68.66 Mil Enterprise Value: 65.37 Mil PE Ratio: 0 PB Ratio: 14.00 GF Score: 0/100

Q4 2023 Pharmaxis Ltd Activities Report Call Transcript

Jul 31, 2023 / NTS GMT
Release Date Price: A$0.054 (+8.00%)
Operator

Good afternoon, everyone. Our clock has now ticked pass midday. So we'll get started with today's quarterly investor briefing with Pharmaxis CEO, Gary Phillips, who also has some updates from the FDA. My name is Alfred, I'm part of Pharmaxis Investor Relations team, I will assist in running call. (Operator Instructions)

It's obviously a very busy day on the AXS explained the last day of month. And there's plenty of information for investors to dissect, including these new FDA developments with Pharmaxis. So Gary, I won't take up anymore of your time. Let me hand over to you.

Gary Phillips
Pharmaxis Ltd - CEO

Thanks, Alfred, and good afternoon, everybody. I presented a couple of investor meetings in the last few weeks and today is a good chance to pull some of the threads that have been going on together and draw some conclusions about where we are as a company right now. Because obviously, we released lot of data in the last couple of months. I'm just going to go through the highlights of what we've announced. And then as Alfred say, I'm very happy to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot